PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|September 21, 2015
Global Closure Systems Exhibits at CPhI 2015
GCS’s latest innovations that will be presented at the show include standard and bespoke closures, oral dose measuring, dispensing syringes, and other medical devices.
Advertisement
Global Closure Systems (GCS), a supplier of plastic closure solutions, announced that it will be exhibiting at this year’s CPhI in Madrid. Its portfolio of products includes Clic-Loc, Mediloc, CapePharma, PharmaSafe, and Vistop.
GCS manufactures child-resistant closures, tamper-evident closures, droppers, and medical devices, and provides closure and dispensing solutions for liquid and solid pharmaceutical products. The company has recently extended its closures range (Flip-loc, Lite-Loc) and developed an innovative bi-injected thermoplastic elastomer closure for large-volume parenterals using blow-fill-seal technology.
Visitors at the show can learn more about GCS’s latest innovations, which include standard and bespoke closures, oral dose measuring, dispensing syringes, and other medical devices.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement